Guardant Health, which develops applied sciences for precision oncology, launched a original collaboration with Story to mix its portfolio of cancer tests within the Story digital health file.
WHY IT MATTERS
Company officers teach the original partnership will mark it more straightforward for health programs, neighborhood companies and retail clinics to invent suppose ordering, access and present of Guardant Health blood tests. The integration will give physicians access to take a look at results within their clinical workflows so that they are able to mercurial mark told therapy choices for patients.
The collaboration will enable companies to “without complications expose Guardant Health tests and access results mercurial, giving them beyond regular time to focal point on their patients,” acknowledged Helmy Eltoukhy, Guardant Health co-CEO. “The integration of our tests with Story, which will embrace Guardant SHIELD, our blood take a look at to display conceal for early signs of colorectal cancer, will abet to amplify the scale and adoption of our choices in each neighborhood practices and big health programs.”
The integration is anticipated to be whole in the 2d half of of this one year.
When it’s miles, companies can expose tests – moreover collectively with Guardant360 CDx, a liquid biopsy that can detect genetic mutations came all the arrangement by arrangement of in circulating cell-free DNA, and Guardant360 Response, a blood take a look at that detects changes in circulating tumor DNA – electronically for the 250 million patients with Story charts.
THE LARGER TREND
Story has been busy honest honest currently, with announcements at HIMSS22 collectively with original SaaS-based shared atmosphere, aimed at self sustaining clinical groups, called Backyard Design; a original buyer relationship management machine, called Cheers; and a original tool, is known as Most effective Esteem My Affected person, that can abet clinicians benchmark effective most efficient practices when put next with mates all the arrangement by arrangement of the country.
This isn’t any longer the first precision medication collaboration for Story both. This previous summer season, Foundation Treatment launched a original partnership with the company to mix its genomic profiling and attempting out services and products into the EHR.
Here is appropriate files, as disciplines corresponding to precision oncology and pharmacogenomics mark giant strides, but challenges with files management and EHR workflow every so continuously abate forward momentum. Click on here to read our interview with UPMC Chief Medical Knowledge Officer Dr. Robert Bart on that topic and others. And click on on here to invent insights into various CIOs’ five-one year plans for precision medication and genomics.
ON THE RECORD
“Our shared commitment to healthcare innovation makes this partnership a pure match that will profit clinicians and patients alike,” added Alan Hutchison, vice president of population health at Story. “Guardant Health’s integration with Story will present a more straightforward and further atmosphere pleasant workflow for clinicians to indicate cancer tests and access accurate-time results, giving companies the files they settle on to mark the ideal care decision for his or her patients.”
Twitter: @MikeMiliardHITN
Electronic mail the author: mike.miliard@himssmedia.com
Healthcare IT News is a HIMSS e-newsletter.
GIPHY App Key not set. Please check settings